Upadacitinib 15 mg plus a 26-week GC taper outperformed placebo in combination with a 52-week GC taper for the treatment of ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% <br / ...

Initiated the Phase 2 MoonStone trial, a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial, to evaluate the efficacy and safety of obexelimab in patients with Relapsing Multiple ...

This article explores the feasibility of simulated placements, incorporating digital technologies alongside classroom-based ...

CENDIFOX: Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers. The trial has completed ...

The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

These accessibility settings will change the way you use your phone, whether you have a disability or simply want to make ...